MWNA
ACOR

Marshall Wace North America’s Acorda Therapeutics ACOR Stock Holding History

Marshall Wace North America’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-220
Closed -$54K – 1697
2019
Q4 		$54K Sell
220
-646
-75% -$163K ﹤0.01% 1147
2019
Q3 		$299K Buy
866
+295
+52% +$160K ﹤0.01% 891
2019
Q2 		$526K Buy
571
+456
+397% +$560K ﹤0.01% 881
2019
Q1 		$183K Buy
+115
New +$207K ﹤0.01% 1004
2017
Q4 		– Sell
-627
Closed -$1.81M – 1674
2017
Q3 		$1.81M Buy
627
+97
+18% +$256K 0.01% 820
2017
Q2 		$1.27M Buy
+530
New +$1.05M 0.01% 860
2013
Q4 		$1.6M Sell
456
-588
-56% -$2.29M 0.03% 317
2013
Q3 		$4.29M Buy
+1,044
New +$4.5M 0.13% 182

Other funds holding ACOR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Marshall Wace North America's ACOR Position: Q1 2020 in Review

Marshall Wace North America sold out of Acorda Therapeutics (ACOR) in Q1 2020, closing a stake of 220 shares — an estimated $54K sold.

Marshall Wace North America first reported a position in ACOR in Q3 2013 and held it in 8 quarters. The position peaked at $4.29M in Q3 2013. 106 funds tracked by Wall St. Rank hold ACOR as of Q1 2020.

  • Marshall Wace North America reported no remaining Acorda Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Marshall Wace North America sold 220 Acorda Therapeutics shares in Q1 2020, an estimated $54K.
  • Marshall Wace North America first reported a position in Acorda Therapeutics in Q3 2013 and held it in 8 quarters.
  • Marshall Wace North America's Acorda Therapeutics position peaked at $4.29M in Q3 2013.
  • 106 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2020.

Based on Marshall Wace North America's 13F filing for Q1 2020, filed 15 May 2020.